Company intelligence / Profile preview
SOLA Biosciences
Boston/Natick, Massachusetts, United Statessola-bio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
SOLA's lead candidate SOL-257 has shown promising preclinical results in ALS models, demonstrating potential to delay disease progression and prolong lifespan in ALS model animals[1][4]. The company presented preclinical proof-of-concept data for SOL-257 at Neuroscience 2023 and ALS One Symposium[4].
- Therapeutic areas
- Neurology
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on SOLA Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOLA Biosciences.